Clinical Trial Search

Primary: Change From Baseline at End of Treatment Period (at 60 Hours) in Hamilton Rating Scale for Depression (HAM-D) Total Score — -8.75; -20.97 score on a scale — p=0.008

Primary: Number of Subjects Experiencing Adverse Events as a Measure of Safety and Tolerability — 4; 1; 1; 0 Participants

Primary: Overall Response Rate — 156; 145 Participants

Primary: Number of Participants With qRT-PCR or Culture-confirmed Influenza-like Illness — 160; 138; 74; 60 Participants

Primary: Success and Failure Rates for Each Treatment Method — 6; 3; 5; 3 Participants

Primary: Efficacy: Percentage of Subjects With a ≥ 75% Decrease in PASI (PASI 75) at Week 16 (Double-blind Period)--LOCF and Observed — 8.7; 9.1; 19.0; 7.7 Percentage of…

Primary: Objective Response Rate — 0; 0 Participants

Primary: Change From Baseline in Caregiver Burden Scores on the Zarit Caregiver Burden Inventory — -2.38; 0.22 change units on a scale — p=.483

Primary: Optic Nerve Sheath Diameter — 4.0; 3.6; 4.2; 3.5 millimeters

Primary: Western Ontario Rotator Cuff Index (WORC) — 39.2; 40.2; 44.5; 40.7 percentage

Primary: Mean Glucose — 182; 165; 181; 165 mg/dl

Primary: Part 1 Pharmacokinetics: t(1/2) for Belumosudil Tablet and [14C]-KD025 IV — 5.298; 5.857 Hours

Primary: Change in TSLP Gene Expression — 0.000197; 0.000035 Fold Change

Primary: Time Spent With CGM Glucose Levels >180mg/dl Between Two Groups — 46.3; 38.5 percentage of time spent >180 mg/dL

Primary: Change in Live Feedback Test Scores From Day 10 to Day 20 — 1.7; 1.7; 0.1; 0.1 units on a scale